NEW YORK (GenomeWeb) – Transgenomic today announced that it has signed an agreement to sell roughly $3 million in restricted stock and warrants through a private placement.

According to the company, the placement includes 1.5 million shares of restricted common stock, as well as fully paid prefunded warrants to purchase up to approximately 700,000 shares of its common stock, in each case at a purchase price of $1.42 per share.

During early morning trading on the Nasdaq, shares of Transgenomic were trading down 7 percent at $1.55.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Researchers have sequenced the northern white rhinoceros to gauge whether it could be brought back from the edge of extinction, the New York Times reports.

Bavaria expands its forensic genetic analyses to include DNA phenotyping, raising discrimination concerns.

Tufts University researchers found a role for miRNA in transmitting stress between generations, the Economist reports.

In Science this week: gut microbiome influences liver cancer growth, spread; and more.